Cipla Limited — Acyclovir Exporter Profile
Indian Pharmaceutical Exporter · #7 for Acyclovir · $1.9M export value · DGFT Verified
Cipla Limited is the #7 Indian exporter of Acyclovir with $1.9M in export value and 68 verified shipments. Cipla Limited holds a 1.5% market share in Acyclovir exports across 6 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Acyclovir Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Acyclovir?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SOUTH AFRICA | $690.8K | 16 | 45.3% |
| AUSTRALIA | $307.4K | 18 | 20.2% |
| UNITED STATES | $265.2K | 9 | 17.4% |
| SINGAPORE | $137.5K | 6 | 9.0% |
| NEW ZEALAND | $110.4K | 5 | 7.2% |
| MADAGASCAR | $13.3K | 14 | 0.9% |
Cipla Limited exports Acyclovir to 6 countries. The largest destination is SOUTH AFRICA accounting for 45.3% of Cipla Limited's Acyclovir shipments, followed by AUSTRALIA (20.2%) and UNITED STATES (17.4%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Acyclovir from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MEDPRO PHARMACEUTICA (PTY) LTD | SOUTH AFRICA | $390.8K | 10 |
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $265.2K | 9 |
| KEY PHARMACEUTICALS PTY LTD | AUSTRALIA | $151.2K | 5 |
| SUCCESS INTER LINK PTE LTD | SINGAPORE | $137.5K | 6 |
| HELLMANN WORLDWIDE LOGISTICS | NEW ZEALAND | $110.4K | 5 |
| NOUMED PHARMACEUTICALS PTY LTD | AUSTRALIA | $105.5K | 9 |
| MEDPRO PHARMACEUTICA PTY LTD | SOUTH AFRICA | $100.0K | 2 |
| CIPLA SELECT (PTY) LTD | SOUTH AFRICA | $50.0K | 1 |
| MEDPRO PHARMACEUTICA (PTY) LTD. | SOUTH AFRICA | $50.0K | 1 |
| MEDPRO PHARMACEUTICA PTY LIMITED | SOUTH AFRICA | $50.0K | 1 |
Cipla Limited supplies Acyclovir to 16 buyers globally. The largest buyer is MEDPRO PHARMACEUTICA (PTY) LTD (SOUTH AFRICA), followed by CIPLA USA INC UPS SUPPLY CHAIN SOLU (UNITED STATES) and KEY PHARMACEUTICALS PTY LTD (AUSTRALIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Acyclovir Export Value and How Much Does Cipla Limited Contribute?
India exported $36.5M worth of Acyclovir through 5,956 shipments from 358 suppliers to 152 countries, serving 879 buyers globally. Cipla Limited contributes $1.9M to this total, accounting for 1.5% of India's Acyclovir exports. Cipla Limited ships Acyclovir to 6 countries through 16 buyers.
What Is the Average Shipment Value for Cipla Limited's Acyclovir Exports?
Cipla Limited's average Acyclovir shipment value is $28.0K per consignment, based on 68 shipments totaling $1.9M. The largest destination is SOUTH AFRICA (45.3% of Cipla Limited's Acyclovir exports).
How Does Cipla Limited Compare to Other Indian Acyclovir Exporters?
Cipla Limited ranks #7 among 358 Indian Acyclovir exporters with a 1.5% market share. The top 3 exporters are HETERO LABS LIMITED ($16.4M), ZYDUS LIFESCIENCES LIMITED ($4.3M), MYLAN LABORATORIES LIMITED ($4.2M). Cipla Limited processed 68 shipments to 6 destination countries.
What Acyclovir Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ACITAB 400 DT TAB (ACYCLOVIR 400MG) [153 | $100.0K | 2 |
| ACITAB 400 DT TAB (ACYCLOVIR 400MG) [151 | $100.0K | 2 |
| VALACYCLOVIR TABS USP 500MG NDC No 6909715305 ANDA No 77135 1 X 90S X 6201 PACK 558090 NUM | $100.0K | 2 |
| ACITOP CREAM ACYCLOVIR CREAM 5%W/W | $100.0K | 2 |
| VALCIVIR 1MG TABLETS (VALACYCLOVIR1000MG) INV.QTY.9865 PACK 5X3'S=147975 NOS | $88.2K | 3 |
| ACITAB 400 DT TAB (ACYCLOVIR 400MG) [15130(PACKS)X6X10'S] | $87.1K | 3 |
| BLISTEX ANTIVIRAL COLD SORE CREAM ACYCLOVIR CREAM 5%W/W | $74.4K | 2 |
| VALACYCLOVIR TABS USP 500MG NDC No. 6909 | $50.0K | 1 |
| ACITOP CREAM (ACYCLOVIR CREAM 5%W/W) (1X | $50.0K | 1 |
| VALACYCLOVIR TABS USP 1 GM NDC No 6909715412 ANDA No 77135 1 X 500S X 552 PACK 276000 NUM | $50.0K | 1 |
Cipla Limited exports 43 distinct Acyclovir formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ACITAB 400 DT TAB (ACYCLOVIR 400MG) [153 with 2 shipments worth $100.0K.
Regulatory Requirements: Exporting Acyclovir to Key Markets
What Cipla Limited must comply with to export Acyclovir to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Acyclovir Exporters?
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | EUGIA PHARMA SPECIALITIES LIMITED | $2.9M | 58 | 2 | $50.0K |
| 3 | AUROBINDO PHARMA LTD | $2.0M | 41 | 2 | $50.0K |
| 7 | CIPLA LIMITED ★ | $1.9M | 68 | 6 | $28.0K |
| 8 | V S INTERNATIONAL PRIVATE LIMITED | $1.3M | 37 | 1 | $35.6K |
| 9 | JODAS EXPOIM PRIVATE LIMITED | $750.0K | 15 | 1 | $50.0K |
Cipla Limited ranks #7 among 358 Indian Acyclovir exporters. Average shipment value of $28.0K compared to the market average of $101.9K. The closest competitors by value are EUGIA PHARMA SPECIALITIES LIMITED and AUROBINDO PHARMA LTD.
Which Indian Ports Ship Acyclovir Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 1,255 | 21.1% |
| DELHI AIR CARGO ACC (INDEL4) | 938 | 15.7% |
| SAHAR AIR | 878 | 14.7% |
| DELHI AIR | 615 | 10.3% |
| Bombay Air | 249 | 4.2% |
| NHAVA SHEVA SEA (INNSA1) | 195 | 3.3% |
| Delhi Air | 188 | 3.2% |
| Bombay Air Cargo | 113 | 1.9% |
Geopolitical & Trade Policy Impact on Cipla Limited's Acyclovir Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Acyclovir, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Acyclovir — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Acyclovir shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 68 individual customs records matching Cipla Limited exporting Acyclovir, covering 43 formulations to 6 countries via 16 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 152+ countries, 879+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Acyclovir Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Acyclovir exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Acyclovir Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Acyclovir. For current shipment-level data, contact TransData Nexus.